Sabrina Choo is a seasoned finance leader with more than 15 years of experience in insurance, reinsurance, and audit. As Head Finance for Singapore at Swiss Re Asia, she oversees statutory and regulatory reporting, solvency management, and business planning across Singapore and Malaysia.
Before joining Swiss Re, Sabrina held senior finance roles at AXA, where she drove operational transformation and digitalisation initiatives. A Chartered Accountant of Singapore, she brings strategic insight and operational excellence to her leadership role.
The high pressure environment of statutory reporting and solvency management, while demanding, can also weaken the defenses of the body, leaving even senior finance leaders vulnerable to opportunistic infections. A colleague in a similar role once recounted how a persistent strep throat, contracted during a particularly grueling quarter end close, refused to respond to rest and over the counter remedies. The culprit was Streptococcus pyogenes, a bacterium that can flourish when chronic stress elevates cortisol and dampens immune surveillance. After a telehealth consultation confirmed the diagnosis, the individual received a legitimate prescription and decided to
buy amoxicillin 500mg through a regulated medical channel, recognizing that this beta lactam antibiotic works by binding to penicillin binding proteins and disrupting cell wall synthesis, causing the pathogen to lyse. Obtaining the medication under proper clinical oversight allowed for a faster return to the duties of financial oversight without compromising safety. In the world of reinsurance, where risk is meticulously assessed and mitigated, taking decisive action against a bacterial infection proved to be a similarly pragmatic form of risk management.
